The purpose of this study is to assess the efficiency and safety of vinorelbine in the treatment of relapsed / advanced ALCL in children and adolescents.
Full Title of Study: “Phase II Study of Vinorelbine for Children With Recurrent Anaplastic Large Cell Lymphoma”
- Study Type: Interventional
- Study Design
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Primary Purpose: Treatment
- Masking: None (Open Label)
- Study Primary Completion Date: December 2024
Anaplastic large cell lymphoma (ALCL) is a rare non-Hodgkin's lymphoma, around 30% patients would get relapse. Vinorelbine(Navelbine) is a third-line treatment option for Hodgkin's disease(HD) after transplantation failed, while both HD and ALCL express CD30. When ALCL recurred, vinblastine monotherapy was used and the 5-year EFS up to 30%, 5-year OS up to 60%. In China vinblastine is unavailable. Vinorelbine is very similar to vinblastine in molecular formula, and is available in China. From November 2016 to March 2017, two patients with recurrent ALCL were recruited in the Department of Hematology and Oncology, Shanghai Children's Medical Center. They received vinorelbine monotherapy and achieved clinical remission (PET CR) at 8 weeks. One patient with bone marrow recurrence showed negative ALK / NPM by PCR . Based on this, the investigators will expand the sample to further investigate the therapeutic efficiency and safety of vinorelbine in children and adolescents with ALCL.
- Drug: Vinorelbine
- During each course, patients will be treated with vinorelbine (25mg/m2/week on weeks 1-3). After 1 course(4 weeks) of vinorelbine, response will be evaluated by simple assessment: clinical symptoms, signs, B ultrasound, chest X-ray, peripheral blood test and bone marrow smear(if needed). After 2 courses, response will be evaluatedy by simple assessment, CT and FDG-PET. The CR/CRu was defined by anatomic tumour shrinkage more than 75% after 2 courses based on CT with negative PET assessment, with negative bone marrow PCR(if needed) and without CNS involvement. Patients who achieved a CR/CRu after two courses either will proceed to stem cell transplantation (SCT) or will receive additional courses of therapy while awaiting SCT. Response was re-evaluated at the end of every 2 courses. Patients with progressive disease at any time during treatment will be removed from protocol therapy.
Arms, Groups and Cohorts
- Experimental: Vinorelbine monotherapy treatment
- Patients will be treated with Vinorelbine. Four weeks as a course. There are 20 courses in total.
Clinical Trial Outcome Measures
- Progression Rate
- Time Frame: 4 weeks
- The progression rate will be obtained from the results of simple assessment after one course.
- CR/CRu Rate
- Time Frame: 8 weeks
- The CR/CRu rate will be obtained from the results of simple assessment, CT and FDG-PET after two courses.
- Progression-free Survival
- Time Frame: 2 years
- Overall Survival
- Time Frame: 2 years
- Compared with historical data.
Participating in This Clinical Trial
Children and adolescents with a clear diagnosis of recurrent / progressive ALCL at Shanghai Children's Medical Center or other centers since September 2017 include: Diagnosed as ALCL, already received first-line treatment, but get disease progression; After receiving ALCL treatment has got CR then diagnosed relapse, need for pathological diagnosis. Exclusion Criteria:
Patients with other systemic diseases, severe infections or critically illness.
Gender Eligibility: All
Minimum Age: N/A
Maximum Age: 18 Years
Are Healthy Volunteers Accepted: No
- Lead Sponsor
- Children’s Cancer Group, China
- Provider of Information About this Clinical Study
- Overall Official(s)
- Yijin Gao, MD, Principal Investigator, Shanghai Children’s Medical Center
- Overall Contact(s)
- Yijin Gao, MD, 86-21-38626161, email@example.com
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.